New drug combo aims to fight tough kidney cancers
NCT ID NCT05665361
First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 5 times
Summary
This study tests two drugs—palbociclib (a daily pill) and sasanlimab (a monthly injection)—in people with advanced kidney cancer (clear cell or papillary type). The goal is to see if the combination can shrink tumors or stop them from growing. About 100 adults will take part for up to 2 years, with regular scans and blood tests to monitor progress.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Palbociclib (a pill) and sasanlimab (an injection)
- What this could lead to
- If it works, this combination could offer a new treatment option for people with advanced kidney cancer that hasn't responded to other therapies.
- What could go wrong
- This is an early-phase trial with only 100 participants, so results may not apply to everyone. The drugs may cause side effects or not shrink tumors as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CARCINOMA (CCRCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.